Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Gabriel Steg

Showing results (11-20 of 242) with videos related to

Pageof 25
Sort By:
Circulation|March 9, 2007
Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concernEdoardo Camenzind, P Gabriel Steg, William Wijns
JAMA|June 22, 2021
Effect of Restrictive or Liberal Blood Transfusion on Major Cardiovascular Events in Patients With Acute Myocardial Infarction and Anemia-ReplyGregory Ducrocq, Tabassome Simon, P Gabriel Steg, et al.
The New England Journal of Medicine|April 25, 2019
Cardiovascular Risk Reduction with Icosapent Ethyl. ReplyDeepak L Bhatt, P Gabriel Steg, Michael Miller
JAMA|February 7, 2013
β-Blocker use for patients with or at risk for coronary artery disease--replySripal Bangalore, P Gabriel Steg, Deepak L Bhatt
The New England Journal of Medicine|April 14, 2021
Cardiovascular Outcomes with Sotagliflozin. ReplyDeepak L Bhatt, P Gabriel Steg, Bertram Pitt
The New England Journal of Medicine|May 23, 2019
Alirocumab after Acute Coronary Syndrome. ReplyGregory G Schwartz, P Gabriel Steg, Michael Szarek
Journal of the American College of Cardiology|February 21, 2004
News from the European Society of Cardiology congress in Vienna, August 30 to September 3, 2003Otto A Smiseth, P Gabriel Steg, Karin Sipido, et al.
Circulation|November 16, 2020
Response by Schwartz et al to Letter Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial"Gregory G Schwartz, Michael Szarek, Vera A Bittner, et al.
Lancet (London, England)|September 2, 2008
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trialKim Fox, Ian Ford, P Gabriel Steg, et al.
Journal of the American College of Cardiology|August 9, 2008
A meta-analysis that misses the markVladimír Dzavík, P Gabriel Steg, Bruce Barton, et al.
Pageof 25

Showing results (11-20 of 242) with videos related to

Sort By:
Pageof 25
Circulation|March 9, 2007
Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concernEdoardo Camenzind, P Gabriel Steg, William Wijns
JAMA|June 22, 2021
Effect of Restrictive or Liberal Blood Transfusion on Major Cardiovascular Events in Patients With Acute Myocardial Infarction and Anemia-ReplyGregory Ducrocq, Tabassome Simon, P Gabriel Steg, et al.
The New England Journal of Medicine|April 25, 2019
Cardiovascular Risk Reduction with Icosapent Ethyl. ReplyDeepak L Bhatt, P Gabriel Steg, Michael Miller
JAMA|February 7, 2013
β-Blocker use for patients with or at risk for coronary artery disease--replySripal Bangalore, P Gabriel Steg, Deepak L Bhatt
The New England Journal of Medicine|April 14, 2021
Cardiovascular Outcomes with Sotagliflozin. ReplyDeepak L Bhatt, P Gabriel Steg, Bertram Pitt
The New England Journal of Medicine|May 23, 2019
Alirocumab after Acute Coronary Syndrome. ReplyGregory G Schwartz, P Gabriel Steg, Michael Szarek
Journal of the American College of Cardiology|February 21, 2004
News from the European Society of Cardiology congress in Vienna, August 30 to September 3, 2003Otto A Smiseth, P Gabriel Steg, Karin Sipido, et al.
Circulation|November 16, 2020
Response by Schwartz et al to Letter Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial"Gregory G Schwartz, Michael Szarek, Vera A Bittner, et al.
Lancet (London, England)|September 2, 2008
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trialKim Fox, Ian Ford, P Gabriel Steg, et al.
Journal of the American College of Cardiology|August 9, 2008
A meta-analysis that misses the markVladimír Dzavík, P Gabriel Steg, Bruce Barton, et al.
Pageof 25